Neurimmune is a biopharmaceutical company focused on translating human immune memory into antibody therapeutics. The company operates in the biopharmaceutical market, primarily targeting neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis (ALS). Neurimmune's business model involves discovering and developing antibody-based therapies and then licensing these discoveries to larger pharmaceutical companies for further development and commercialization. For instance, Neurimmune discovered aducanumab, an antibody for Alzheimer's disease, which was licensed to Biogen for further development and submission to the U.S. Food and Drug Administration (FDA). The company generates revenue through licensing agreements, research collaborations, and milestone payments from its partners. Neurimmune serves a global market, collaborating with both academic institutions and industry partners to advance its pipeline of therapeutic candidates. The company's innovative approach leverages the natural immune response to create treatments that can potentially transform the lives of patients with debilitating diseases.

Keywords: biopharmaceutical, antibody therapeutics, neurodegenerative diseases, Alzheimer's, Parkinson's, ALS, licensing, collaborations, immune memory, clinical trials, innovative treatments.